These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35428720)

  • 41. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort.
    Vallejo-Yagüe E; Burkard T; Micheroli R; Burden AM
    BMJ Open; 2022 Sep; 12(9):e061474. PubMed ID: 36115672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Nguyen D; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2018 Jul; 57(7):1253-1263. PubMed ID: 29635379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
    Rahman P; McInnes IB; Deodhar A; Schett G; Mease PJ; Shawi M; Cua DJ; Sherlock JP; Kollmeier AP; Xu XL; Sheng S; Ritchlin CT; McGonagle D
    Clin Rheumatol; 2024 May; 43(5):1591-1604. PubMed ID: 38472528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
    Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
    Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population.
    Łosińska K; Michelsen B; Kavanaugh A; Korkosz M; Haugeberg G
    Scand J Rheumatol; 2024 Jan; 53(1):10-20. PubMed ID: 37656147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
    Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
    Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
    Ogdie A; Liu M; Glynn M; Emeanuru K; Harrold LR; Richter S; Guerette B; Mease PJ
    J Rheumatol; 2021 May; 48(5):693-697. PubMed ID: 33191289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
    Gladman DD; Kavanaugh A; Gómez-Reino JJ; Wollenhaupt J; Cutolo M; Schett G; Lespessailles E; Guerette B; Delev N; Teng L; Edwards CJ; Birbara CA; Mease PJ
    RMD Open; 2018; 4(1):e000669. PubMed ID: 30018799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials.
    Curtis JR; Deodhar A; Soriano ER; Rampakakis E; Shawi M; Shiff NJ; Han C; Tillett W; Gladman DD
    Rheumatol Ther; 2024 Sep; ():. PubMed ID: 39261446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
    Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
    Schoels MM; Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.